Outside of the significantly greater use of natalizumab in the people with clinicaly isolated syndrome/relapsing-remitting multiple sclerosis, both groups received similar DMT protocol with the majority of people with progressive multiple sclerosis continuing their IFN-β and glatiramer acetate treatment. The gene discussed is IFNB1; the disease is relapsing-remitting multiple sclerosis.